Simplifying the complexities of rare disease research
Regulatory incentives such as the orphan products designation and the availability of Pediatric Rare Disease Priority Review Vouchers have increased the drive for rare disease research. But with each potential new therapy, biopharma companies are charting new paths through clinical development, with limited disease knowledge, complex regulatory pathways, few suitable patients and unknown obstacles ahead. Quintiles is an experienced partner who can help you simplify the complexities of rare disease research to speed new treatments to market for patients and their families.
Solution tailored to rare disease studies
Through our experience conducting more than 245 rare disease studies in 96 countries since 2011, Quintiles has developed a comprehensive yet flexible solution to these complex and challenging studies.
Click below to read below about Quintiles patient-centric rare disease capabilities.
For those who can overcome the challenges, there are many opportunities in rare disease product development. Quintiles is an experienced partner who can help you manage the unexpected.
From identifying outcome measures that demonstrate safety and efficacy to generating the real-world evidence that payers are looking for, we are here to offer the specialized scientific, clinical and operational expertise you need to bring rare disease therapeutics to patients and their families.